2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LA
➤ Gửi thông báo lỗi ⚠️ Báo cáo tài liệu vi phạmNội dung chi tiết: 2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LA
2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LA
Proprietary Information of United Healthcare: The information contained in this de_________ .proprietary and the sole property of United Healthcare Se 2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LAervices, Inc. Unauthorized copying, use anddistribution of this information are strictly prohibited Copyright 2019 United Healthcare Services, Inc.I UnitedHealthcareCommunity PlanUnitedHealthcare® Community PlanMedical PolicyMOLECULAR ONCOLOGY TESTING FOR CANCER DIAGNOSIS, PROGNOSIS, AND TREATMENT D 2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LAECISIONSI Policy Number CS152 EEEffective Date October 1. 2019TBDTable of ContentsPageAPPLICATION................................... 1COVERAGE RATIONA2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LA
LE............................ 1DEFI.NJTJQNS...................................3APPLICABLE CODES...............................3DESCRIPTION OF SERVICEProprietary Information of United Healthcare: The information contained in this de_________ .proprietary and the sole property of United Healthcare Se 2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LAICAID SERVICES.....31REFERENCES....................................32POLICY HISTQRY/REVISIQN information...........40INSTRUCTIONS FOR USE..........................40Instructions for Use ,Commercial Poli<• Molecular Dncslggy Testing for Cancer Diagnosis. Prognosis, .and Treatment DecisionsMedicare Ad 2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LAvantage Coverage Summarie:•Genetic Testing•Laboratory Tests and ServicesPPLICATIONThis policy does not apply to the state of Tennessee, refer to the M2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LA
edical Policy titled Molecular Oncology Testing for Cancer Diagnosis, Prognosis, and Treatment Decisions (for Tennessee Only).LOVERAGE RATIONALEBreastProprietary Information of United Healthcare: The information contained in this de_________ .proprietary and the sole property of United Healthcare Se 2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LA Assay, Breast Cancer Index (BCI) and EndoPredict - is proven and medically necessary to make a treatment decision regarding adjuvant chemotherapy in females or males with non-metastatic breast cancer in the following situations•Newly diagnosed (within the last 6 months) when all of the following cr 2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LAiteria are met:0 Lymph node negative or 1-3 positive axillary lymph nodes; and0 Hormone receptor-positive (estrogen receptor positive, progesterone re2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LA
ceptor positive or both); and0 HER2 receptor negative, and0 Adjuvant chemotherapy is not precluded due to any other factor (e g . advanced age and/or Proprietary Information of United Healthcare: The information contained in this de_________ .proprietary and the sole property of United Healthcare Se 2019-UHC-214molecular-oncology-testing-cancer-diagnosis-prognosis-treatment-decisions-cs-redline-LA and determined to use the results to guide therapy.Proprietary Information of United Healthcare: The information contained in this de_________ .proprietary and the sole property of United Healthcare SeGọi ngay
Chat zalo
Facebook